JP2025023920A5 - - Google Patents

Download PDF

Info

Publication number
JP2025023920A5
JP2025023920A5 JP2024180002A JP2024180002A JP2025023920A5 JP 2025023920 A5 JP2025023920 A5 JP 2025023920A5 JP 2024180002 A JP2024180002 A JP 2024180002A JP 2024180002 A JP2024180002 A JP 2024180002A JP 2025023920 A5 JP2025023920 A5 JP 2025023920A5
Authority
JP
Japan
Prior art keywords
antibody
alk5 inhibitor
antigen
binding fragment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024180002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025023920A (ja
JP7798998B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/041291 external-priority patent/WO2020013803A1/en
Application filed filed Critical
Priority to JP2024180002A priority Critical patent/JP7798998B2/ja
Publication of JP2025023920A publication Critical patent/JP2025023920A/ja
Publication of JP2025023920A5 publication Critical patent/JP2025023920A5/ja
Application granted granted Critical
Publication of JP7798998B2 publication Critical patent/JP7798998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024180002A 2018-07-09 2024-10-15 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 Active JP7798998B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180002A JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2018/041291 WO2020013803A1 (en) 2018-07-09 2018-07-09 Antibody-alk5 inhibitor conjugates and their uses
JP2021523548A JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
JP2023080821A JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
JP2024180002A JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023080821A Division JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用

Publications (3)

Publication Number Publication Date
JP2025023920A JP2025023920A (ja) 2025-02-19
JP2025023920A5 true JP2025023920A5 (https=) 2025-02-27
JP7798998B2 JP7798998B2 (ja) 2026-01-14

Family

ID=69142765

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021523548A Active JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
JP2023080821A Active JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
JP2024180002A Active JP7798998B2 (ja) 2018-07-09 2024-10-15 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021523548A Active JP7335957B2 (ja) 2018-07-09 2018-07-09 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
JP2023080821A Active JP7573685B2 (ja) 2018-07-09 2023-05-16 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用

Country Status (7)

Country Link
US (1) US20210299268A1 (https=)
EP (1) EP3820467A4 (https=)
JP (3) JP7335957B2 (https=)
CN (2) CN119488607A (https=)
AU (2) AU2018431586B2 (https=)
CA (1) CA3104934A1 (https=)
WO (1) WO2020013803A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
EP3820467A4 (en) * 2018-07-09 2022-05-04 Synthis Therapeutics, Inc. ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
AU2021205893A1 (en) * 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
US11801304B2 (en) * 2020-02-19 2023-10-31 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
EP4219453A4 (en) * 2020-09-28 2024-10-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PYRAZOLE COMPOUND AND ITS PREPARATION METHOD AND ITS USE
WO2022076905A1 (en) * 2020-10-09 2022-04-14 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN115192731B (zh) * 2021-04-12 2023-09-26 中国科学院上海有机化学研究所 一种抗体药物偶联物的制备方法
WO2023170608A1 (en) * 2022-03-09 2023-09-14 Orum Therapeutics, Inc. Activators of effector t cells
CN121712526A (zh) * 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
WO2004013135A1 (en) * 2002-07-31 2004-02-12 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2007070866A2 (en) 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
CN102159248B (zh) * 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
WO2016115218A1 (en) 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
EP3244926B8 (en) * 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
US20170158772A1 (en) * 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
JP7340458B2 (ja) * 2017-05-09 2023-09-07 アメリカ合衆国 Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
EP3820467A4 (en) 2018-07-09 2022-05-04 Synthis Therapeutics, Inc. ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2025023920A5 (https=)
JP2022046569A5 (https=)
JP2026010000A5 (https=)
JPWO2020122034A5 (https=)
TWI572361B (zh) 肟共軛至酮修飾多肽的方法
JPWO2022102695A5 (https=)
JP7550768B2 (ja) 抗体－薬物コンジュゲート用のグリコシド含有ペプチドリンカー
JP2017537893A5 (https=)
AU5970900A (en) Method for producing an injectable medicament preparation
JPWO2020188061A5 (https=)
JPWO2020031936A5 (https=)
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
CN107043406B (zh) 化合物、连接子-药物、及配体-药物耦合体
JPWO2020118109A5 (https=)
JPWO2021151984A5 (https=)
JP2021525724A (ja) プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
JP2003501485A (ja) 担体−薬物複合体
JP2020506685A5 (https=)
JP2024540691A (ja) リン（ｖ）および薬物部分を含むコンジュゲート
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2005501052A5 (https=)
CN108495840A (zh) γ-鹅膏菌素的衍生物
JPWO2021142029A5 (https=)
KR20210125484A (ko) 항체 약물 결합체에 사용되는 약물-링커 mc-mmaf의 제조 방법 및 이의 중간체
JP2023509760A (ja) Ａｌｋ５阻害剤複合体およびその使用